{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T13:18:16Z","timestamp":1778505496599,"version":"3.51.4"},"reference-count":18,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T00:00:00Z","timestamp":1778457600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To investigate the diagnostic value of the PRIMARY score in 18F-PSMA-1007 PET\/CT for prostate cancer (PCa), to compare its diagnostic efficacy with maximum standardized uptake value (SUVmax), and explore the value of their combined model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A total of 180 patients with suspected prostate cancer were initially screened. After excluding 91 patients (70 with prior treatment, 16 without pathological confirmation, 3 with unclear pathological results, and 2 with poor image quality), 89 patients were finally enrolled. We retrospectively reviewed 89 patients with suspected PCa who underwent 18F-PSMA-1007 PET\/CT from November 2023 to September 2025, including 61 with PCa and 28 with benign lesions. All patients underwent standard preoperative evaluation including PSA, digital rectal examination (DRE), ultrasound, or multiparametric MRI (mpMRI) before imaging. Prostate biopsy was performed within 2 weeks before or after PET\/CT according to clinical indications. The SUVmax of the representative lesion was measured and the PRIMARY score was recorded. Intergroup differences were analyzed, optimal cutoff values were determined by ROC curve, and AUCs were compared by the DeLong test. Risk stratification was performed for clinically significant prostate cancer (csPCa), with focus on the combined diagnostic strategy for \u201cgray-zone\u201d lesions with PRIMARY score 4. Interobserver agreement was evaluated using the Kappa coefficient.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Age was comparable between the two groups (\n                      <jats:italic>P<\/jats:italic>\n                      &amp;gt; 0.05), while SUVmax and PRIMARY score were significantly different (both\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt; 0.05). The PRIMARY score showed excellent interobserver agreement (Kappa = 0.903). For PCa diagnosis, the AUCs of SUVmax, PRIMARY score, and the combined index PRE were 0.921, 0.960, and 0.963, and PRE was significantly superior to SUVmax alone, but not significantly different from PRIMARY score. For csPCa, the positive predictive value was 97.6% for PRIMARY score 5, 68.2% for score 4, and increased to 85.7% by applying the combined criterion (PRIMARY = 4 and SUVmax \u2265 7.5). Notably, 3 of 8 patients in the PRIMARY = 4 and SUVmax &amp;lt; 7.5 subgroup still had csPCa, indicating a trade\u2013off between PPV and missed csPCa. PRIMARY score \u2264 3 showed a low csPCa prevalence of 7.7%.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In 18F-PSMA-1007 PET\/CT, the PRIMARY score demonstrates comparable diagnostic efficacy to SUVmax with excellent reproducibility. The combined PRE model was superior to SUVmax alone, but not significantly different from PRIMARY score in this cohort, optimizing the stratification of PRIMARY score 4 \u201cgray-zone\u201d lesions. This approach effectively reduces false positives and provides a robust quantitative reference for biopsy decisions and individualized patient management.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1829352","type":"journal-article","created":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T12:47:56Z","timestamp":1778503676000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Diagnostic value of PRIMARY score and a combined model with SUVmax in 18F-PSMA-1007 PET\/CT for prostate cancer"],"prefix":"10.3389","volume":"13","author":[{"given":"Futian","family":"Hu","sequence":"first","affiliation":[{"name":"The Second Affiliated Hospital of Guangxi Medical University","place":["Nanning, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiangru","family":"Li","sequence":"additional","affiliation":[{"name":"The Second Affiliated Hospital of Guangxi Medical University","place":["Nanning, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zonglin","family":"Li","sequence":"additional","affiliation":[{"name":"The Second Affiliated Hospital of Guangxi Medical University","place":["Nanning, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiqiang","family":"Huang","sequence":"additional","affiliation":[{"name":"The Second Affiliated Hospital of Guangxi Medical University","place":["Nanning, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenjie","family":"Liu","sequence":"additional","affiliation":[{"name":"The Second Affiliated Hospital of Guangxi Medical University","place":["Nanning, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shidong","family":"Lian","sequence":"additional","affiliation":[{"name":"The Second Affiliated Hospital of Guangxi Medical University","place":["Nanning, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiquan","family":"Liu","sequence":"additional","affiliation":[{"name":"The Second Affiliated Hospital of Guangxi Medical University","place":["Nanning, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries.","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin."},{"key":"B2","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s00259-023-06392-0","article-title":"The diagnostic accuracy of radiolabeled psma-ligand pet for tumour staging in newly diagnosed prostate cancer patients compared to histopathology: a systematic review and meta-analysis.","volume":"51","author":"Gossili","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","article-title":"Prostate-specific membrane antigen pet-ct in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (propsma): a prospective, randomised, multicentre study.","volume":"395","author":"Hofman","year":"2020","journal-title":"Lancet."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.3390\/cancers14061479","article-title":"Comparison of [(18)f]psma-1007 with [(68)ga]ga-psma-11 pet\/ct in restaging of prostate cancer patients with psa relapse.","volume":"14","author":"Hoffmann","year":"2022","journal-title":"Cancers."},{"key":"B5","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s13550-020-00730-1","article-title":"The value of (18)f-psma-1007 pet\/ct in identifying non-metastatic high-risk prostate cancer.","volume":"10","author":"Hong","year":"2020","journal-title":"Ejnmmi Res."},{"key":"B6","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s40644-023-00627-x","article-title":"Evaluating the value of (18)f-psma-1007 pet\/ct in the detection and identification of prostate cancer using histopathology as the standard.","volume":"23","author":"Luo","year":"2023","journal-title":"Cancer Imaging."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.2967\/jnumed.121.263448","article-title":"The primary score: using intraprostatic (68)ga-psma pet\/ct patterns to optimize prostate cancer diagnosis.","volume":"63","author":"Emmett","year":"2022","journal-title":"J Nucl Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"94","DOI":"10.2967\/jnumed.123.266164","article-title":"Reproducibility and accuracy of the primary score on psma pet and of pi-rads on multiparametric mri for prostate cancer diagnosis within a real-world database.","volume":"65","author":"Emmett","year":"2024","journal-title":"J Nucl Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"9237","DOI":"10.1097\/JS9.0000000000004733","article-title":"Avoiding unnecessary biopsy in suspicious prostate cancer using primary score =3 and psad = 0.2 ng\/ml\/cm3: a real-world, dual-center study from china.","volume":"112","author":"He","year":"2026","journal-title":"Int J Surg"},{"key":"B10","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1007\/s00345-025-05981-y","article-title":"Exploration of a novel quantitative model based on primary score in the diagnosis of clinically significant prostate cancer using [18f]psma pet\/ct.","volume":"43","author":"Gao","year":"2025","journal-title":"World J Urol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"2804","DOI":"10.1007\/s00259-025-07148-8","article-title":"Pathological and radiological features of false-positive lesions on [(68)ga]ga-psma-11 pet\/ct in primary staging of prostate cancer: a radio-pathology matching analysis.","volume":"52","author":"Li","year":"2025","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"B12","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.eururo.2025.08.005","article-title":"Sparc: the standardised prostate-specific membrane antigen positron emission tomography\/computed tomography analysis and reporting consensus: a delphi analysis.","volume":"89","author":"Herrmann","year":"2025","journal-title":"Eur Urol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1007\/s00259-023-06556-y","article-title":"Prediction of clinically significant prostate cancer by [(68) ga]ga-psma-11 pet\/ct: a potential tool for selecting patients for active surveillance.","volume":"51","author":"Akcay","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"B14","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s13139-025-00920-6","article-title":"Primary score as a predictive marker in intermediate-risk prostate cancer: insights from psma pet\/ct imaging.","volume":"59","author":"Evangelista","year":"2025","journal-title":"Nucl Med Mol Imaging."},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-025-07731-z","article-title":"The integrated diagnostic strategy of performing psma pet\/ct followed by mri improves the diagnostic accuracy of prostate cancer.","author":"Ma","year":"2026","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"B16","doi-asserted-by":"publisher","first-page":"291","DOI":"10.3760\/cma.j.cn112137-20240715-01614","article-title":"[A comparative study on the diagnostic value of (18)f-psma pet\/ct primary score and psma expression score for clinically significant prostate cancer].","volume":"105","author":"Zhu","year":"2025","journal-title":"Zhonghua Yi Xue Za Zhi."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4274\/mirt.galenos.2025.16023","article-title":"Improved accuracy and reliability of primary scoring using delayed [(68)ga] ga-psma pet\/ct imaging.","volume":"34","author":"Ak\u00e7ay","year":"2025","journal-title":"Mol Imaging Radionucl Ther."},{"key":"B18","doi-asserted-by":"publisher","first-page":"555","DOI":"10.2967\/jnumed.123.266742","article-title":"The value of (68)ga-psma pet\/mri for classifying patients with pi-rads 3 lesions on multiparametric mri: a prospective single-center study.","volume":"65","author":"Shi","year":"2024","journal-title":"J Nucl Med."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1829352\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T12:47:57Z","timestamp":1778503677000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1829352\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,11]]},"references-count":18,"alternative-id":["10.3389\/fmed.2026.1829352"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1829352","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,11]]},"article-number":"1829352"}}